Can tolerability make petrelintide competitive in obesity?

Although Zealand’s petrelintide has fallen short of other clinical amylin programs on efficacy, its benign tolerability profile highlights the promise of the target in obesity. The question is whether petrelintide will be differentiated enough on tolerability to become the therapy of choice if other amylin programs deliver greater weight loss.

Zealand Pharma A/S (CSE:ZEAL) and partner Roche (SIX:ROG; OTCQX:RHHBY) will aim to answer that question in Phase III. In the Phase II ZUPREME-1 trial, petrelintide monotherapy produced placebo-adjusted weight loss of up to 9% at 42 weeks, putting it closer to cagrilintide monotherapy from Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) than to the nearly 20% weight loss reported for eloralintide monotherapy in a Phase II trial from Eli Lilly and Co. (NYSE:LLY)...